Breast cancer - capecitabine

The clinical effectiveness and cost effectiveness of capecitabine for breast cancer

Status:	History
Expected date of issue:	May 2003
Wave:	6
Process:	MTA
Topic area: Cancer

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Anne-Toni Rodgers
Technical Lead:	Dr Alec Miners
Communications manager:	Lucy Betterton
Project manager:	Nina Pinwill
Assessment group:	NHS Centre for Reviews and Dissemination, University of York

Top

 

Provisional schedule

Information meeting with consultees:	06 June 2002
Closing date for invited submissions / evidence submission:	08 July 2002
1st appraisal committee meeting:	13 November 2002
2nd appraisal committee meeting	11 February 2003

Top

 

Consultees and Commentators

Consultees Commentators (no right of appeal) Manufacturers / Sponsors Roche Royal Pharmaceutical Society Royal College of Physicians Royal College of Nursing Royal College of Surgeons Royal College of Radiologists British Psychosocial Oncology Society Royal College of General Practitioners British Association of Surgical Oncology Breast Surgery Special Interest Group British Association of Plastic Surgeons Medical Women's Federation British Oncological Association Welsh Cancer Network British Oncology Pharmacy Association (BOPA) Macmillan Cancer Relief Marie Curie Cancer Care National Cancer Alliance Long Term Medical Conditions Alliance Cancer BACUP Cancer Research UK Breast Cancer Care Breakthrough Breast Cancer UK Breast Cancer Coalition Breast Cancer Campaign Department of Health Welsh Assembly Government East Lancashire Health Authority Dorset Health Authority Health Technology Board for Scotland National Coordinating Centre for Health Technology Assessment NHS CRD, University of York Health Development Agency National Council for Hospice & Specialist Palliative Care Services National Cancer Research Institute The Institute of Cancer Research MRC Clinical Trials Unit Cancer Guidance Steering Group Patient / Carer Groups None Professional Groups None Others None   General None Comparator Manufacturers None Assessment Team None Associated Guideline Groups None Associated Public Health Groups None Research Groups None

Top

 

Project history

Date Summary 22 May 2002 List of consultees added. 22 May 2002 Changes to dates of second appraisal meeting and expected date of issue. 18 June 2002 Scope and protocol published on website. 7 January 2003 ACD and assesment report published. 4 April 2003 FAD published

Top

 

Key documents

Final Appraisal Determination - Capecitabine for the treatment of locally advanced or metastatic breast cancer 04 April 2003 Appraisal Consultation Document: Capecitabine for the treatment of locally advanced or metastatic breast cancer 07 January 2003 Scope: Capecitabine for metastatic breast cancer 18 June 2002 Protocol: Capecitabine for metastatic breast cancer 18 June 2002 A rapid and systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer 07 January 2003

This page was last updated:   04 April 2003